COVID-19 long-acting antibodies discovered by Vanderbilt University Medical Center move to phase 3 clinical trials
Oct. 13, 2020—AstraZeneca is advancing into phase 3 clinical trials with an investigational COVID-19 therapy of two long-acting antibodies discovered by Vanderbilt University Medical Center and optimized by AstraZeneca.
Oct. 31, 2019—Short of mandating universal diabetes treatment, regular exercise and low-calorie diets, little can be done to stem the rising tide of kidney failure — unless scientists can figure out why exactly the kidney’s filtration units, the glomeruli, stop working.
Jun. 18, 2019—A study published June 17 in Nature offers clues as to why blocking inhibitory receptors on tumor-infiltrating T cells may not always work
Feb. 13, 2019—Using sophisticated gene sequencing and computing techniques, researchers at Vanderbilt University Medical Center and the San Diego Supercomputer Center have achieved a first-of-its-kind glimpse into how the body’s immune system gears up to fight off infection.
Mar. 16, 2017—Researchers at Vanderbilt University Medical Center (VUMC) have mapped the conformational changes that occur in a protein “notorious” for pumping chemotherapeutic drugs out of cancer cells and blocking medications from reaching the central nervous system.
Nov. 7, 2016—Researchers at Vanderbilt University Medical Center and Washington University School of Medicine in St. Louis have isolated a human monoclonal antibody that in a mouse model “markedly reduced” infection by the Zika virus.
Aug. 11, 2016—Hypoxia (lack of enough oxygen) is bad for the body as a whole, but in the neighborhood where infection-fighting antibodies arise, may be important for keeping proper order.
Jan. 26, 2012—Investigators at Vanderbilt-Ingram Cancer Center and several other centers may be one step closer to finding out why some melanoma patients relapse after treatment with a promising new drug.